NASDAQ:ADGI - Adagio Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $14.50
  • Forecasted Upside: 453.44 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.62
▼ -0.01 (-0.38%)

This chart shows the closing price for ADGI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adagio Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADGI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADGI

Analyst Price Target is $14.50
▲ +453.44% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Adagio Therapeutics in the last 3 months. The average price target is $14.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 453.44% upside from the last price of $2.62.

This chart shows the closing price for ADGI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Adagio Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2022Morgan StanleyLower Price TargetUnderweight$3.00High
5/13/2022Stifel NicolausLower Price Target$9.00 ➝ $5.00Medium
1/6/2022Morgan StanleyDowngradeOverweight ➝ Underweight$6.00High
12/22/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$46.00 ➝ $10.00Low
12/15/2021GuggenheimDowngradeBuy ➝ NeutralHigh
12/14/2021Stifel NicolausDowngradeBuy ➝ Hold$50.00 ➝ $9.00High
12/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$49.00 ➝ $11.00High
11/29/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$33.00 ➝ $49.00High
9/20/2021Jefferies Financial GroupInitiated CoverageBuy$60.00Medium
8/31/2021GuggenheimInitiated CoverageBuy$40.00High
8/31/2021Stifel NicolausInitiated CoverageBuy$57.00High
8/31/2021Jefferies Financial GroupInitiated CoverageBuy$60.00High
8/31/2021Morgan StanleyInitiated CoverageEqual Weight$33.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 7 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
12/27/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/25/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2022
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
4/26/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Adagio Therapeutics logo
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $2.62
Low: $2.48
High: $2.66

50 Day Range

MA: $3.51
Low: $2.56
High: $5.02

52 Week Range

Now: $2.62
Low: $2.46
High: $78.82

Volume

1,089,585 shs

Average Volume

3,406,618 shs

Market Capitalization

$287.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Adagio Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Adagio Therapeutics in the last twelve months: Guggenheim, Jefferies Financial Group Inc., Morgan Stanley, and Stifel Nicolaus.
View the latest analyst ratings for ADGI.

What is the current price target for Adagio Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Adagio Therapeutics in the last year. Their average twelve-month price target is $14.50, suggesting a possible upside of 453.4%.
View the latest price targets for ADGI.

What is the current consensus analyst rating for Adagio Therapeutics?

Adagio Therapeutics currently has 1 sell rating and 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ADGI, but not buy more shares or sell existing shares.
View the latest ratings for ADGI.

How do I contact Adagio Therapeutics' investor relations team?

The company's listed phone number is 603-252-2274 and its investor relations email address is [email protected] The official website for Adagio Therapeutics is adagiotx.com. Learn More about contacing Adagio Therapeutics investor relations.